14 results about "Peptide ligand" patented technology

The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase – 1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

The application discloses a polypeptide ligand SR-22 targeting a membrane protein of a pathogenic oomycete and an application thereof, and the amino acid sequence of the polypeptide ligand SR-22 is SRITRLLRGSGSGSSRITRLLR. The polypeptide ligand SR-22 provided by the application can significantly inhibit the growth of various crop pathogenic oomycetes, and can well inhibit the infection of pathogenic bacteria and prevent the occurrence of diseases in practical application, and can be developed into a novel targeted polypeptide pesticide for green prevention and control of crop oomycete diseases.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

This invention discloses a class of polypeptide ligands that can specifically bind to and / or significantly promote the assembly of Holliday linkers and their applications, belonging to the field of biomedical technology. The general formula for the amino acid sequence of the polypeptide ligand is: AX₄BQX₃CXn, where A and B are each independently selected from any one of phenylalanine, tryptophan, tyrosine, lysine, and arginine; C is selected from any one of arginine and lysine; X represents any amino acid; and n is an integer ranging from 0 to 4. The advantages of this invention are: the polypeptide provided by this invention has a high affinity for Holliday linkers (HJs), a strong ability to promote HJ formation, and exhibits certain antitumor activity against human liver cancer cells A549.

The application relates to a method for generating a target AAV9 antibody epitope affinity peptide ligand by using a protein language model and a screening method and application thereof, and relates to an affinity peptide candidate sequence construction and screening method, an affinity peptide ligand, an affinity medium and application thereof for targeting adeno-associated virus type 9 (AAV9). The AAV9 capsid region recognized by Fab2-4 is taken as a target, structure analysis, natural amino acid positioning, key residue extraction and affinity peptide template construction are carried out, a candidate peptide library is generated by using a protein language model, and a candidate affinity peptide ligand is screened by combining molecular docking, binding free energy evaluation, refined docking and molecular dynamics simulation. The affinity peptide ligand is any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4, can be immobilized on a solid phase matrix to form an affinity medium, is used for AAV9 recognition, capture and purification, and provides a technical scheme for AAV9 purification process development.

This application discloses an affinity short peptide ligand and its application, wherein the affinity short peptide ligand can specifically bind to anti-CD3 antibodies or their antigen-binding fragments. This invention provides a binding short peptide with high specificity and high affinity for CD3ε antibodies (e.g., SP34), which, as a ligand for affinity chromatography packing materials, achieves efficient purification of TCE bispecific / polyclonal antibodies, filling a technological gap in this field.

The present invention relates to a Bicycle toxin conjugate BT8009, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

This invention relates to the bicyclic toxin complex BT5528 or its pharmaceutically acceptable salts, or its pharmaceutical composition, and its use.

In the treatment of patients with tumors (especially malignant tumors), the substances phenoxythiamine (B-OT) and / or oxothiamine (OT) are administered as active ingredients concurrently with ongoing radionuclide therapy (RNT) (particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT)). B-OT and / or OT administration is cyclical, meaning that dosing phases of B-OT and / or OT (“B-OT / OT dosing cycles”) alternate with treatment intervals (dosing intervals). During each B-OT / OT dosing cycle, B-OT and / or OT are administered at a predetermined dose (mg / kg patient body weight) for one or more consecutive days. This is followed by a treatment interval during which neither B-OT nor OT is administered, before the next B-OT / OT dosing cycle begins.

Provided herein are bicyclic peptide ligands specific for transferrin receptor 1 (TfRl). Also provided are pharmaceutical compositions comprising the peptide ligands, and uses of the peptide ligands and pharmaceutical compositions in preventing, inhibiting, or treating a disease or disorder through TfRl-mediated delivery of a therapeutic agent.

This invention relates to peptide ligands capable of binding to TLR3. Specifically, the invention describes bicyclic peptide ligands comprising the peptide ligand described herein and a molecular scaffold, wherein three cysteine ​​residues of the peptide ligand are covalently bonded to the molecular scaffold to form two circular sequences. The invention also includes pharmaceutical compositions, polymeric binding complexes, and pharmaceutical conjugates comprising the said peptide ligand, and the use of the said peptide ligand in the prevention, inhibition, or treatment of TLR3-mediated diseases or conditions, such as autoimmune diseases, inflammatory conditions, and cancer.